vs
Side-by-side financial comparison of ACADIA REALTY TRUST (AKR) and RHYTHM PHARMACEUTICALS, INC. (RYTM). Click either name above to swap in a different company.
ACADIA REALTY TRUST is the larger business by last-quarter revenue ($103.0M vs $57.3M, roughly 1.8× RHYTHM PHARMACEUTICALS, INC.). ACADIA REALTY TRUST runs the higher net margin — 135.1% vs -83.0%, a 218.0% gap on every dollar of revenue. On growth, RHYTHM PHARMACEUTICALS, INC. posted the faster year-over-year revenue change (36.9% vs -1.3%). Over the past eight quarters, RHYTHM PHARMACEUTICALS, INC.'s revenue compounded faster (48.5% CAGR vs 7.0%).
Acadia Realty Trust is a publicly traded real estate investment trust (REIT) that specializes in owning, operating, and redeveloping high-quality retail and mixed-use properties, primarily in dense, high-barrier-to-entry U.S. markets. Its portfolio includes neighborhood shopping centers, urban street retail assets, and community-focused mixed-use developments.
Rhythm Pharmaceuticals is a biopharmaceutical firm focused on developing and commercializing targeted therapies for rare genetic disorders causing severe unmanageable obesity, including POMC deficiency, LEPR deficiency, and Bardet-Biedl syndrome. It serves patients in North America and Europe who lack effective standard treatments for their chronic life-altering conditions.
AKR vs RYTM — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $103.0M | $57.3M |
| Net Profit | $139.1M | $-47.5M |
| Gross Margin | — | 91.6% |
| Operating Margin | 153.9% | -82.2% |
| Net Margin | 135.1% | -83.0% |
| Revenue YoY | -1.3% | 36.9% |
| Net Profit YoY | -58.2% | -9.6% |
| EPS (diluted) | — | $-0.73 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $103.0M | — | ||
| Q4 25 | — | $57.3M | ||
| Q3 25 | — | $51.3M | ||
| Q2 25 | — | $48.5M | ||
| Q1 25 | — | $32.7M | ||
| Q4 24 | $93.3M | $41.8M | ||
| Q3 24 | $87.7M | $33.3M | ||
| Q2 24 | $87.3M | $29.1M |
| Q1 26 | $139.1M | — | ||
| Q4 25 | — | $-47.5M | ||
| Q3 25 | — | $-52.9M | ||
| Q2 25 | — | $-46.6M | ||
| Q1 25 | — | $-49.5M | ||
| Q4 24 | $1.2M | $-43.3M | ||
| Q3 24 | $12.3M | $-43.6M | ||
| Q2 24 | $1.6M | $-32.3M |
| Q1 26 | — | — | ||
| Q4 25 | — | 91.6% | ||
| Q3 25 | — | 89.3% | ||
| Q2 25 | — | 88.6% | ||
| Q1 25 | — | 88.8% | ||
| Q4 24 | — | 90.9% | ||
| Q3 24 | — | 88.5% | ||
| Q2 24 | — | 89.9% |
| Q1 26 | 153.9% | — | ||
| Q4 25 | — | -82.2% | ||
| Q3 25 | — | -102.6% | ||
| Q2 25 | — | -93.4% | ||
| Q1 25 | — | -143.7% | ||
| Q4 24 | 17.5% | -98.6% | ||
| Q3 24 | 19.9% | -132.0% | ||
| Q2 24 | 20.4% | -139.2% |
| Q1 26 | 135.1% | — | ||
| Q4 25 | — | -83.0% | ||
| Q3 25 | — | -103.1% | ||
| Q2 25 | — | -96.1% | ||
| Q1 25 | — | -151.4% | ||
| Q4 24 | 1.2% | -103.6% | ||
| Q3 24 | 14.0% | -131.2% | ||
| Q2 24 | 1.8% | -110.9% |
| Q1 26 | — | — | ||
| Q4 25 | — | $-0.73 | ||
| Q3 25 | — | $-0.82 | ||
| Q2 25 | — | $-0.75 | ||
| Q1 25 | — | $-0.81 | ||
| Q4 24 | $0.08 | $-0.71 | ||
| Q3 24 | $0.07 | $-0.73 | ||
| Q2 24 | $0.01 | $-0.55 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $31.4M | $388.9M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $2.6B | $139.1M |
| Total Assets | $4.5B | $480.2M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $31.4M | — | ||
| Q4 25 | — | $388.9M | ||
| Q3 25 | — | $416.1M | ||
| Q2 25 | — | $291.0M | ||
| Q1 25 | — | $314.5M | ||
| Q4 24 | $16.8M | $320.6M | ||
| Q3 24 | $46.2M | $298.4M | ||
| Q2 24 | $31.9M | $319.1M |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $1.5B | — | ||
| Q3 24 | $1.6B | — | ||
| Q2 24 | $1.7B | — |
| Q1 26 | $2.6B | — | ||
| Q4 25 | — | $139.1M | ||
| Q3 25 | — | $148.8M | ||
| Q2 25 | — | $-11.9M | ||
| Q1 25 | — | $18.9M | ||
| Q4 24 | $2.1B | $21.7M | ||
| Q3 24 | $1.9B | $11.2M | ||
| Q2 24 | $1.8B | $39.3M |
| Q1 26 | $4.5B | — | ||
| Q4 25 | — | $480.2M | ||
| Q3 25 | — | $506.9M | ||
| Q2 25 | — | $372.7M | ||
| Q1 25 | — | $386.7M | ||
| Q4 24 | $4.4B | $392.3M | ||
| Q3 24 | $4.3B | $363.6M | ||
| Q2 24 | $4.3B | $381.8M |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.74× | — | ||
| Q3 24 | 0.82× | — | ||
| Q2 24 | 0.95× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $-25.4M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | 1.7% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | — | $-25.4M | ||
| Q3 25 | — | $-26.6M | ||
| Q2 25 | — | $-23.3M | ||
| Q1 25 | — | $-40.4M | ||
| Q4 24 | $140.4M | $-18.8M | ||
| Q3 24 | $44.6M | $-25.2M | ||
| Q2 24 | $32.0M | $-29.1M |
| Q1 26 | 1.7% | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 121.08× | — | ||
| Q3 24 | 3.64× | — | ||
| Q2 24 | 20.25× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AKR
| Rental | $98.6M | 96% |
| Other | $4.4M | 4% |
RYTM
Segment breakdown not available.
